Delivering specialized pulmonary expertise, deep community roots, and efficient trial execution between Nashville and Murfreesboro, Tennessee.
Delivering specialized pulmonary expertise, deep community roots, and efficient trial execution between Nashville and Murfreesboro, Tennessee.
Smyrna Advanced Research is a dedicated community-based clinical research site in Smyrna, Tennessee, serving a diverse patient population across the greater Nashville and Murfreesboro region. Led by board-certified principal investigator Dr. Prakash Patel, our site brings more than 25 years of clinical expertise in pulmonology, internal medicine, and metabolic conditions, offering sponsors and CROs a reliable clinical research center in Smyrna with a well-established local patient base built over two decades.
As a proud member of the ECN Clinical, Smyrna Advanced Research operates under centralized SOPs, unified contracting, and network-wide quality standards, giving sponsors and CROs the consistency of a national network with the responsiveness of a dedicated community site.
Smyrna Advanced Research conducts clinical research across three therapeutic areas under the leadership of board-certified principal investigator Dr. Prakash Patel. The site brings deep expertise in pulmonary clinical research in Smyrna, including COPD, ILD, chronic cough, and pulmonary fibrosis, alongside internal medicine clinical research and metabolic clinical research serving the greater Tennessee region.
Our patient recruitment infrastructure combines technology, community relationships, and dedicated outreach to deliver consistent enrollment performance across every study we support.
Smyrna Advanced Research serves a diverse adult patient population across Smyrna and the greater Nashville corridor in Tennessee. Our centrally located site supports clinical research patient recruitment in Smyrna through an active internal referral network of 10+ providers, a 40-mile catchment radius, and a patient-first care model that prioritizes retention and engagement throughout every study.
Our Smyrna location gives Smyrna Advanced Research access to a growing and diverse Tennessee community in one of the state's fastest-expanding regions. With a broad patient base and a bilingual team supporting both English and Spanish-speaking participants, our site ensures every participant is fully informed and supported throughout their study journey.
Diversity in clinical research is a commitment to the communities we serve. Our sites are chosen and structured to reflect the communities they serve, ensuring every study benefits from genuine local representation, trust, and accessibility.
Our network capability deck or TA-specific one-pagers to share with your team.
Yes. Smyrna Advanced Research offers paid clinical research opportunities in Smyrna, Tennessee and across the greater Nashville and Murfreesboro region. Compensation varies by study and will be explained clearly before you enroll. Study-related medical care and visits are always at no cost to participants.
Smyrna Advanced Research is a dedicated clinical research center in Smyrna, conveniently located between Nashville and Murfreesboro and serving participants across a 40-mile catchment radius throughout middle Tennessee.
Smyrna Advanced Research is a CLIA-certified clinical research site in Smyrna TN offering Phase II through IV capabilities. Our site features onsite ECG, cold chain and temperature-controlled drug storage, DEA license, CTMS and multiple EDC platforms, eConsent, and specialty procedures including biopsies, infusion, PK sampling, spirometry, oscillometry, FeNO, and certified FibroScan.
Smyrna Advanced Research conducts pulmonary clinical research, internal medicine clinical research, and metabolic clinical research in Smyrna, led by board-certified principal investigator Dr. Prakash Patel with more than 25 years of clinical expertise.
Yes. Smyrna Advanced Research is a dedicated clinical research site for sponsors and CROs, operating as part of the ECN Clinical under centralized SOPs, unified contracting, and network-wide quality standards. Sponsors and CROs benefit from a proven 85% screen to enroll rate, 91% patient retention rate, and startup timelines consistently under four weeks.
